What question did this study set out to answer?

Assess the effect of dupilumab on inducing clinical remission in at-risk individuals with type-2 inflammatory asthma.

April 15, 2026Open Access

Protocol for a multinational, investigator-initiated, parallel group, randomised, double-blind, placebo-controlled phase 3b superiority trial assessing the effect of dupilumab on inducing clinical remission outcomes in at-risk type-2 inflammatory asthma (HOTHOT)

Key Points

Assess the effect of dupilumab on inducing clinical remission in at-risk individuals with type-2 inflammatory asthma.
Multinational, investigator-initiated design
Parallel group randomised trial
Double-blind and placebo-controlled setup
Adheres to SPIRIT 2025 guidelines
Results will be reported at international meetings
Findings will be published in peer-reviewed journals

Abstract

Approved by the Research Ethics Committee of CIUSSS de l'Estrie-CHUS (MP-31-2026-6116). The protocol follows SPIRIT 2025 guidelines. Results will be disseminated at international meetings and in peer-reviewed journals in accordance with CONSORT.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Simon Couillard

Nayia Petousi

Sanjay Ramakrishnan

Journals

Annals of Allergy Asthma & Immunology

Actions

Institutions

University of Oxford

McGill University Health Centre

Université de Sherbrooke

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Protocol for a multinational, investigator-initiated, parallel group, randomised, double-blind, placebo-controlled phase 3b superiority trial assessing the effect of dupilumab on inducing clinical remission outcomes in at-risk type-2 inflammatory asthma (HOTHOT)

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider